ArticleCancer science2025
Impact of TP53, KRAS, and APC Mutations on Neoadjuvant Chemotherapy Outcomes in Locally Advanced Rectal Cancer.
Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multifaceted Anticancer Activity of Flavanone/Chromanone Intermediates for Five-Membered Heterocyclic Derivatives: Targeting Oxidative Stress, Apoptosis, and MAPK Signaling in Colorectal Cancer.Molecules (Basel, Switzerland) · 2026Article
- Beyond Pleiotropy: A Call for Target Deconvolution and Chemopreventive Repositioning of Alkaloids in CRC [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Despite recent advances in neoadjuvant strategies for locally advanced rectal cancer (LARC), optimal chemotherapy regimens and the role of genetic biomarkers in guiding treatment remain unclear. Moreover, predictive markers are urgently needed for radiation-sparing strategies. Therefore, we aimed to assess the predictive and prognostic value of TP53, KRAS, and APC mutations in patients with LARC undergoing neoadjuvant chemotherapy (NACT) by retrospectively analyzing 43 patients with LARC who underwent NACT without radiation. Treatment response was assessed using RECIST criteria, revealing that 55.8% of patients exhibited a complete or partial response, which was significantly correlated with improved recurrence-free survival (p = 0.015). Conversely, tumor regression grade (TRG) did not predict survival outcomes. Targeted amplicon sequencing of pre-treatment biopsy and surgical specimens revealed high mutation frequencies in TP53 (74.4%), KRAS (44.1%), and APC (32.5%). TP53 mutations included diverse alterations, particularly gain-of-function missense variants, reflected in distinct immunohistochemical patterns. KRAS mutations mainly affected codon 12, and APC mutations were predominantly truncating. Notably, KRAS + APC co-mutations, observed in 11.6% of patients, were significantly associated with poor overall survival (p = 0.046), suggesting a synergistic role in poor prognosis. Conversely, patients with TP53 mutations exhibited improved survival (p = 0.007), underscoring their potential as favorable prognostic markers. Therefore, specific genetic alterations influence both prognosis and response to chemotherapy, offering critical insights into personalized treatment planning. Incorporating comprehensive molecular profiling-particularly TP53, KRAS, and APC mutation status-for preoperative evaluation may refine risk stratification, inform surgical decision-making, and support tailored therapeutic approaches in LARC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.